DexCom — May 1, 2025 release

“As we progress through 2025, we will advance our product portfolio with the launch of our Dexcom G7 15 Day system and continue to advocate for expanded global access to our glucose biosensors.” 2025 Annual Guidance and $750 Million Share Repurchase Program Dexcom is updating fiscal year 2025 guidance for Non-GAAP Gross Profit Margin, and reiterating guidance for Revenue, Non-GAAP Operating Margin, and Adjusted EBITDA Margin at the following levels: • Revenue of $4.60 billion (14% growth) • Non-GAAP Gross Profit Margin of approximately 62%. The reduction relative to prior guidance primarily results from incremental costs related to near-term supply dynamics that were previously disclosed as the company reestablishes optimal finished goods inventory levels. • Non-GAAP Operating Margin of approximately 21% • Adjusted EBITDA Margin of approximately 30% The company also announced a $750 million share repurchase program in conjunction with first quarter results. First Quarter 2025 Financial Results Revenue: In the first quarter of 2025, worldwide revenue grew 12% to $1.036 billion on a reported basis, up from $921.0 million in the first quarter of 2024. Gross Profit: GAAP gross profit totaled $589.0 million or 56.9% of revenue for the first quarter of 2025, compared to $561.9 million or 61.0% of revenue in the first quarter of 2024. Non-GAAP gross profit* totaled $596.2 million or 57.5% of reported revenue for the first quarter of 2025, compared to $569.1 million or 61.8% of reported revenue in the first quarter of 2024. 1 First quarter 2025 organic revenue was $1.046 billion and excludes $9.9 million of foreign exchange impact. First quarter 2024 reported